Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
143M
-
Number of holders
-
197
-
Total 13F shares, excl. options
-
112M
-
Shares change
-
-534K
-
Total reported value, excl. options
-
$2.63B
-
Value change
-
-$30.3M
-
Put/Call ratio
-
3.78
-
Number of buys
-
96
-
Number of sells
-
-95
-
Price
-
$23.56
Significant Holders of Dyne Therapeutics, Inc. - Common Stock (DYN) as of Q4 2024
239 filings reported holding DYN - Dyne Therapeutics, Inc. - Common Stock as of Q4 2024.
Dyne Therapeutics, Inc. - Common Stock (DYN) has 197 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 112M shares
of 143M outstanding shares and own 78.29% of the company stock.
Largest 10 shareholders include Atlas Venture Life Science Advisors, LLC (8.02M shares), FMR LLC (8M shares), BlackRock, Inc. (7.95M shares), JANUS HENDERSON GROUP PLC (7.38M shares), VANGUARD GROUP INC (6.7M shares), RA CAPITAL MANAGEMENT, L.P. (6.38M shares), FCPM III SERVICES B.V. (5.46M shares), RTW INVESTMENTS, LP (5.22M shares), STATE STREET CORP (3.72M shares), and CITADEL ADVISORS LLC (2.86M shares).
This table shows the top 197 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.